Bacitracin EP Impurity C
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Bacitracin EP Impurity C

● Auf Lager

Katalog-Nr.::VE0026806
CAS-Nr.::N/A
Summenformel::C64H99N17O16S
Molare Masse::1394.7 g/mol

Zusätzliche Informationen zu

Parent drug

Bacitracin

IUPAC-Name

4,10-anhydro[N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazol-4-yl]carbonyl]-L-leucyl-D-α-glutamyl-L-valyl-L-lysyl-D-ornithyl-L-valyl-D-phenylalanyl-L-histidyl-D-α-aspartyl-L-asparagine]

Pharmacopeial Synonyms

Bacitracin D3; Bacitracin C1a

Synonyme

N/A

Beschreibung

Bacitracin EP Impurity C is an identified process-related and degradation impurity observed during bacitracin manufacturing and stability studies. It exhibits a distinct chromatographic retention relative to the bacitracin major components and is routinely detected by validated HPLC-UV and LC-MS assays as part of impurity profiling. Structural elucidation relies on high-resolution mass spectrometry and NMR following isolation. Its presence, origin, and levels are monitored under pharmacopoeial and ICH impurity control strategies to ensure product quality. Control measures include optimization of fermentation parameters, purification sequence, and stability-indicating analytical methods with defined identification, qualification, and specification thresholds.

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url